Skip to main content
SpringerLink
Log in

Urate-Lowering Therapy: Current Options and Future Prospects for Elderly Patients with Gout

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Gout is increasingly seen in the elderly population, in large part due to physiological decline in renal function with age, and as a result of therapy for comorbidities, in particular the use of diuretic therapies for hypertension and congestive heart failure. Urate-lowering therapy (ULT) is the cornerstone of successful long-term gout management with the aim of achieving a sustained reduction in urate (<0.36 mmol/L, or lower [<0.30 mmol/L] in those with tophi). After decades during which there has been relatively little interest in developing new agents to treat gout, the last 5–10 years has seen a plethora of new agents with several now used in routine clinical practice. There has also been a renewed focus on the optimal use of established ULT, specifically allopurinol, which remains the first-line therapy for most patients. There is emerging data on its use in patients with renal impairment and better recognition of risk factors of the rare but potentially lethal allopurinol hypersensitivity syndrome (AHS). Febuxostat, a new xanthine oxidase inhibitor, is now established in everyday practice. Uricosuric agents may be indicated in certain patient groups, whilst a new class of recombinant uricases (pegloticase) given by intravenous infusion may achieve dramatic and rapid urate-lowering effects. Cost and other factors have thus far limited its use to the very severe cases. Furthermore, increased understanding of urate metabolism has led to the development of a number of drugs currently under clinical evaluation. Common therapeutic targets are the urate transporters in the kidney and alternative xanthine oxidase inhibition pathways. These advances bode well for the better management of gout and hyperuricaemia in our elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mikuls T, Farrar J, Bilker W, Fernandes S, Schumacher HR, Saag K. Gout epidemiology: results from the UK general practice research database, 1990–1999. Ann Rheum Dis. 2005;64:267–72.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Khanna D, Fitzgerald J, Khanna P, Sangmee B, Singh M, Neogi T, et al. American College of Rheumatology Guidelines for the Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia. Arthritis Care Res. 2012;64(10):1431–46.

    Article  CAS  Google Scholar 

  3. Loebl WY, Scott JT. Withdrawal of allopurinol in patients with gout. Ann Rheum Dis. 1974;33(4):304–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Gast L. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. Clin Rheumatol. 1987;6(1):70–3.

    Article  PubMed  CAS  Google Scholar 

  5. Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla J. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Care Res. 2006;55(5):786–90.

    Article  CAS  Google Scholar 

  6. Hutton I, Gamble G, Gow P, Dalbeth N. Factors associated with recurrent hospital admissions for gout: a case-controlled study. J Clin Rheumatol. 2009;15(6):271–4.

    Article  PubMed  Google Scholar 

  7. Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen F. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology. 2007;46:1804–7.

    Article  PubMed  CAS  Google Scholar 

  8. Becker M, Schumacher HR, Benjamin K, Gorevic P, Greenwald M, Fessel J, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009;36(5):1041–8.

    Article  PubMed  Google Scholar 

  9. Sivera F, Andrés M, Carmona L, Kydd A, Moi J, Seth R, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328–35.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Becker M, Schumacher HR, Espinoza L, Wells A, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricaemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63. doi:10.1186/ar2978.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hande K, Noone R, Stone W. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47–56.

    Article  PubMed  CAS  Google Scholar 

  12. Hung S, Chung W, Liou L, Chu C, Lin M, Huang H, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci. 2005;102(11):4134–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Vazquez-Mellado J, Meono Morales E, Pacheco-Tena C, Burgos-Vargas R. Relationship between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60:981–3.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Dalbeth N, Kumar S, Stamp LK, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout. J Rheumatol. 2006;33(8):1646–50.

    PubMed  CAS  Google Scholar 

  15. Yun J, Marcaida M, Eriksson K, Jamin H, Fontana S, Pichler W, et al. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential ise of HLA-B*58:01. J Immunol. 2014;192:2984–93.

    Article  PubMed  CAS  Google Scholar 

  16. Stamp L, Taylor W, Jones P, Dockerty J, Drake J, Frampton C, et al. Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529–36.

    Article  PubMed  CAS  Google Scholar 

  17. Stamp L, O’Donnell J, Zhang M, James J, Frampton C, Barclay M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment. Arthritis Rheum. 2011;63(2):412–21.

    Article  PubMed  CAS  Google Scholar 

  18. Venkat Raman G, Sharman V, Lee H. Azathioprine and allopurinol: a potentially dangerous combination. J Int Med. 1990;228:69–71.

    Article  CAS  Google Scholar 

  19. Stamp L, Barclay M, O’Donnell J, Zhang M, Drake J, Frampton C, et al. Furosemide increases plasma oxypurinol without lowering serum urate—a complex drug interaction: implications for clinical practice. Rheumatology. 2012;51(9):1670–6.

    Article  PubMed  CAS  Google Scholar 

  20. Bose B, Badve S, Hiremath S, Boudville N, Brown F, Cass A, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29:406–13.

    Article  PubMed  CAS  Google Scholar 

  21. Krishnan E, Baker J, Furst D, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688–96.

    Article  PubMed  CAS  Google Scholar 

  22. Baker J, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: Recent developments and where do they leave us? Am J Med. 2005;118:816–26.

    Article  PubMed  CAS  Google Scholar 

  23. Norman A, Ang D, Ogston S, Lang C, Struthers A. Effect of high dose allopurinol on exercise in patients withy chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375:2161–7.

    Article  Google Scholar 

  24. Grimaldi-Bensouda L, Alpérovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, et al. Impact of allopurinol on the risk of myocardial infarction. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2012-202972.

    PubMed  Google Scholar 

  25. Thansaaoulis G, Brophy J, Richard H, Pilote L. Gout, allopurinol use and heart failure outcomes. Arch Intern Med. 2010;170(15):1358–64.

    Article  Google Scholar 

  26. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal function. Int Urol Nephrol. 2007;39(4):1227–33.

    Article  PubMed  CAS  Google Scholar 

  27. Feig D, Soletsky B, Johnson R. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension. JAMA. 2010;300(8):924–32.

    Article  Google Scholar 

  28. Becker M, Schumacher HR, Wortmann R, MacDonald P, Eustace D, Palo W, et al. Febuxostat compared with allopurinol in patients with hyperuricaemia and gout. N Engl J Med. 2005;353:2450–61.

    Article  PubMed  CAS  Google Scholar 

  29. Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC Geriatr. 2012;12:11. doi:10.1186/1471-2318-12-11.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  30. Chohan S, Becker M. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011;38(9):1957–9.

    Article  PubMed  CAS  Google Scholar 

  31. Beard S, von Scheele B, Nuki G, Pearson I. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013. doi:10.1007/s10198-013-0486-z.

    PubMed  Google Scholar 

  32. Horikoshi R, Akimoto T, Inoue M, Morishita Y, Kusano E. Febuxostat for hyperuricaemia: experience with patients on chronic hemodialysis treatment. Clin Exp Nephrol. 2013;17:149–50.

    Article  PubMed  Google Scholar 

  33. Tojimbara T, Nakajima I, Yashima J, Fuchinoue S, Teraoka S. Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients. Transplant Proc. 2014;46:511–3.

    Article  PubMed  CAS  Google Scholar 

  34. Sofue T, Inui M, Hara T, Nishijima Y, Moriwaki K, Hayashida Y, et al. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients. Drug Des Dev Ther. 2014;8:245–53.

    Article  Google Scholar 

  35. Kang Y, Kim M, Jang H, Bae E, Yun S, Cho H, et al. Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease. J Clin Pharm Ther. 2014;39:328–30.

    Article  PubMed  CAS  Google Scholar 

  36. Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease. J Clin Pharm Ther. 2013;38:258–61.

    Article  PubMed  CAS  Google Scholar 

  37. Khosravan R, Grabowski B, Mayer M, Wu J, Joseph-Ridge N, Vernillet L. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006;46(1):88–102.

    Article  PubMed  CAS  Google Scholar 

  38. Dore M, Frenette A, Mansour A, Troyanov Y, Begin J. Febuxostat as a novel option to optimize thiopurines’ metabolism in patients with inadequate metabolite levels. Ann Pharmacother. 2014;48(5):648–51.

    Article  PubMed  CAS  Google Scholar 

  39. Wu J, Joseph-Ridge N, et al. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol. 2006;46(8):855–66.

    Article  PubMed  Google Scholar 

  40. Grabowski B, Khosravan R, Wu J, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. Br J Clin Pharmacol. 2010;70(1):57–64.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  41. Khosravan R, Grabowski B, Wu J, et al. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol. 2008;65(3):355–63.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  42. Mukoyoshi M, Nishimura S, Hoshide S, et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008;38(5):496–510.

    Article  PubMed  CAS  Google Scholar 

  43. Whelton A, MacDonald P, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17(1):7–13.

    Article  PubMed  Google Scholar 

  44. Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y, et al. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials. 2014;15:26.

    Article  PubMed  PubMed Central  Google Scholar 

  45. White WB, Chohan S, Dabholkar A, Hunt B, Jackson R. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J. 2012;164(1):14–20. doi:10.1016/j.ahj.2012.04.011.

    Article  PubMed  CAS  Google Scholar 

  46. MacDonald T, Ford I, Nuki G, Mackenzie I, De Caterina R, Findlay E, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014;4(7):e005354. doi:10.1136/bmjopen-2014-.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Reinders M, Van Roon E, Jansen T, Delsing J, Griep E, Hoekstra M, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68:51–6.

    Article  PubMed  CAS  Google Scholar 

  48. Perez-Ruiz F, Calaabozo M, Fernardez-Lopez J, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomised, actively controlled study. J Clin Rheumatol. 1999;5(2):49–55.

    Article  PubMed  CAS  Google Scholar 

  49. Hautekeete M, Henrion J, Naegels S, DeNeve A, Adler M, Deprez C, et al. Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. Liver. 1995;15:25–9.

    Article  PubMed  CAS  Google Scholar 

  50. Lee M-H, Graham G, Williams K, Day R. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interests of patients? Drug Saf. 2008;31(8):643–65.

    Article  PubMed  CAS  Google Scholar 

  51. Kobayashi K, Kajiwara E, Ishikawa M, Oka H, Chiba K. Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes. Biopharm Drug Dispos. 2012;33:466–73.

    Article  PubMed  CAS  Google Scholar 

  52. Scott S, Khasawneh R, Peter I, Kornreich R, Desnick R. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics. 2010;11:781–91.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  53. Roberts R, Wallace M, Wright D, Cadzow M, Dalbeth N, Jones P, et al. Frequency of CYP2C9 polymorphisms in polynesian people and potential relevance to management of gout with benzbromarone. Jt Bone Spine. 2014;81(2):160–3.

    Article  CAS  Google Scholar 

  54. Uchida S, Shimada K, Misaka S, Imai H, Katoh Y, Inui N, et al. Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes. Drug Metab Pharmacokinet. 2010;25:605–10.

    Article  PubMed  CAS  Google Scholar 

  55. Zurcher R, Bock H, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A treated renal transplant patients: a prospective study. Nephrol Dial Transplant. 1994;9:548–51.

    PubMed  CAS  Google Scholar 

  56. Masbernard A, Giudicelli C. Ten years experience with benzbromarone in then management of gout and hyperuricaemia. S Afr Med J. 1981;59:701–6.

    PubMed  CAS  Google Scholar 

  57. Heel R, Brogden R, Speight T, Avery G. Benzbromarone: a review of its pharmacological properties and therapeutic uses in gout and hyperuricaemia. Drugs. 1977;14(5):349–66.

    Article  PubMed  CAS  Google Scholar 

  58. Shimodaira H, Takahashi K, Kano K, Matsumoto Y, Uchida Y, Kudo T. Enhancement of anticoagulant action by warfarin-benzbromarone interaction. J Clin Pharmacol. 1996;36:168–74.

    Article  PubMed  CAS  Google Scholar 

  59. Locuson C, Wahlstrom J, Rock D, Rock D, Jones J. A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab Dispos. 2003;31(7):967–71.

    Article  PubMed  CAS  Google Scholar 

  60. Reinders M, Van Roon E, Houtmann P, Brouwers J, Jansen T. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheum. 2007;26:1459–65.

    Article  Google Scholar 

  61. Stocker S, Williams K, McLachlan A, Graham G, Day R. Pharmacokinetic and Pharmacodynamic Interaction between Allopurinol and Probenecid in Healthy Subjects. Clin Pharmacokinet. 2008;47(2):111–8.

    Article  PubMed  CAS  Google Scholar 

  62. Thompson G, Duff I, Robinson W, Mikkelsen W, Galindez H. Long term uricosuric therapy in gouty. Arthritis Rheum. 1962;5:384–96.

    Article  PubMed  CAS  Google Scholar 

  63. Bartels E, Matossian G. Gout: six-year follow-up on probenecid therapy. Arthritis Rheum. 1959;2(3):193–202.

    Article  PubMed  CAS  Google Scholar 

  64. Pui K, Gow P, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol. 2013;40(6):872–6.

    Article  PubMed  CAS  Google Scholar 

  65. Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43(1):103–8.

    Article  PubMed  CAS  Google Scholar 

  66. Harris M, Bryant L, Danaher P, Alloway J. Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis. J Rheumatol. 2000;27(12):2873–6.

    PubMed  CAS  Google Scholar 

  67. Sundy J, Baraf H, Yood R, Edwards N, Gutierrez-Urena S, Treadwell E, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711–20.

    Article  PubMed  CAS  Google Scholar 

  68. Baraf H, Becker M, Gutierrez-Urena S, Treadwell E, Vazquez-Mellado J, Rehrig C, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013;15:R137.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Lipsky P, Calabrese L, Kavanaugh A, Sundy J, Wright D, Wolfson M, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Hershfield M, Ganson N, Kelly S, Scarlett E, Jaggers D, Sundy J. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther. 2014;16:R63.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Gentry W, Dotson M, Williams B, Hartley M, Stafford K, Bottorff M, et al. Investigation of pegloticase-associated adverse events from a nationwide reporting system database. Am J Health Syst Pharm. 2014;71(9):722–7.

    Article  PubMed  Google Scholar 

  72. Yood R, Ottery F, Irish W, Wolfson M. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. BMC Res Notes. 2014;7:51.

    Article  Google Scholar 

  73. Perez-Ruiz F, Hingorani V, Welp J, Sheedy B, Manhard K, Shen Z, et al. Efficacy and safety of a range of doses of RDEA594, a novel uricosuirc agent, as a single agent in hyperuricaemic gout patients: multicentre, randomized, double-blind, placebbo controlled, phase 2 experience. Ann Rheum Dis. 2010;69(Suppl 3):121.

    Google Scholar 

  74. Perez-Ruiz F, Sundy J, Krishnan E, Hingorani V, Welp J, Suster M, et al. Efficacy and safety of lesinurad (RDEA594), a novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: randomized, double-blind, placebo-controlled, phase 2B study. Ann Rheum Dis. 2011;70(Suppl 3):104.

    Google Scholar 

  75. Fleischmann R, Kerr B, Yeh L-T, Suster M, Shen Z, Polvent E, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology. 2014. doi:10.1093/rheumatology/ket487.

    Google Scholar 

  76. Noveck R, Wang Z, Forsthoefel A, Sigmon K, Hall P, Keogh J, et al. Levotofisopam has uricosuric activity and reduces serum urate levels in patients with gout. Arthritis Rheum. 2012;64(10 (Suppl)):S356.

    Google Scholar 

  77. Hollister A, Becker M, Terkeltaub R, Waugh A, Lyman S, Flynt A, et al. BCX4208 shows synergistic reductions in serum uric acid in gout patients when combined with allopurinol. Ann Rheum Dis. 2011;70(Suppl 3):183.

    Google Scholar 

  78. Dobo S, Flynt A, Hollister A, Sheridan W. BCX4208, A novel urate-lowering therapy, was generally safe and well tolerated in two 3-week studies in gout subjects. Ann Rheum Dis. 2011;70(Suppl 3):188.

    Google Scholar 

  79. Saha G, Karpf D, Choi Y, Roberts B. Arhalofenate, a potential novel treatment for hyperuricemia, with or without metabolic co-morbidities, in patients with gout: meta-analysis of urate lowering in four phase 2 studies in type 2 diabetes. Arthritis Rheum. 2011;63(10 (suppl)):S1014.

    Google Scholar 

  80. Choi Y, Larroca V, Lucman A, Vicena V, Abarca N, Rantz T, et al. Arhalofenate is a novel dual-acting agent with uricosuric and anti-inflammatory properties. Arthritis Rheum. 2012;64(10 (supple)):S697.

    Google Scholar 

  81. Okamoto K, Nishino T. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. J Nippon Med Sch. 2008;75(1):2–3.

    Article  PubMed  Google Scholar 

  82. Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014. (in press).

  83. Sundy J, Kitt M. Tranilast, a novel, potential treatment for the chronic management of hyperuricaemia in patients with gout, reduces serum uric acid in healthy subjects. Ann Rheum Dis. 2010;69(Suppl 3):607.

    Google Scholar 

  84. Mandal A, Emerling D, Serafini T, Mount D. Tranilast inhibits urate transport mediated by URAT1 and GLUT9. Arthritis Rheum. 2010;62(Suppl 10):164.

    Google Scholar 

  85. Miner J, Tan P. RDEA3170, a novoel, high affinity URAT1 inhibitor binds to a central domain with URAT1. Ann Rheum Dis. 2012;71(Suppl 3):446.

    Article  Google Scholar 

  86. Ahn S, Horiba N, Ohtomo, Lee K, Kim K, Kim B, et al. The therapeutic efficacy of the novel uricosuric agent UR-1102 for hyperuricaemia and gout. Ann Rheum Dis. 2013;72(Suppl 3):704.

    Article  Google Scholar 

  87. Warrell R, Klukovits A, Barnes K, Satyanarayana C, Cheeseman C, Piwinski J. Novel bifunctional inhibitors of xanthine oxidase and URAT1 induce profound hypouricaemia in human subjects. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2014-eular.2265.

    Google Scholar 

Download references

Acknowledgments

LKS has received consulting fees from Astra Zeneca. PC declares no conflicts of interest. No funding was used to support the writing of the manuscript.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Otago, Christchurch, P. O. Box 4345, Christchurch, 8140, New Zealand

    Lisa K. Stamp

  2. Department of Rheumatology, Immunology and Allergy, Canterbury District Health Board, Christchurch, New Zealand

    Lisa K. Stamp & Peter T. Chapman

Authors
  1. Lisa K. Stamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter T. Chapman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa K. Stamp.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stamp, L.K., Chapman, P.T. Urate-Lowering Therapy: Current Options and Future Prospects for Elderly Patients with Gout. Drugs Aging 31, 777–786 (2014). https://doi.org/10.1007/s40266-014-0214-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-014-0214-0

Keywords

Search

Navigation